Subscribe To
GNLX / Why Shares of Genelux Corporation Jumped This Week
GNLX News
By Seeking Alpha
July 11, 2023
Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer
Genelux, an immuno-oncology frontrunner, has secured over $65 million in financing and is conducting successful clinical trials for its primary candid more_horizontal
By The Motley Fool
June 1, 2023
Why Shares of Genelux Corporation Jumped This Week
Genelux focuses on hard-to-treat cancers. Its lead therapy is Olvi-Vec, which did well in a phase 2 trial to treat ovarian cancer. more_horizontal
By Seeking Alpha
March 26, 2023
Genelux: Recent IPO With Phase 3 Stage Oncolytic Virus Cancer Therapy
GNLX IPO-ed recently, but the company has been around for two decades. The company develops an oncolytic virus targeting cancer. more_horizontal
By Market Watch
January 26, 2023
Genelux IPO prices at bottom of range
Genelux Corp. priced its initial public offering at $6 a share, the low end of its $6 to $7 a share range, for its stock market debut Thursday on the more_horizontal